Abels, Improved distribution analysis of cobalamins and cobalamin analogues in human plasma in which the use of thiol-blocking agents is a prerequisite, Clinica Chimica Acta, Volume 131, Issue 3, 15 July 1983, Pages 211-224, ISSN 0009-8981 Thakkar, K., & Billa, G
Di BattistaAPRhindSGRichardsDHutchisonMG
Wolverine Stack Daily Blend Reference Total Daily Blend 0.5 mg total BPC-157 Amount 250 mcg TB-500 Amount 250 mcg Common Frequency Commonly described as daily Units From 20 mg Vial + 2 mL 5 units Total Daily Blend 1.0 mg total BPC-157 Amount 500 mcg TB-500 Amount 500 mcg Common Frequency Commonly described as daily Units From 20 mg Vial + 2 mL 10 units Total Daily Blend 1.5 mg total BPC-157 Amount 750 mcg TB-500 Amount 750 mcg Common Frequency Community reference only Units From 20 mg Vial + 2 mL 15 units Total Daily Blend 2.0 mg total BPC-157 Amount 1 mg TB-500 Amount 1 mg Common Frequency Community reference only Units From 20 mg Vial + 2 mL 20 units These schedules come from community use patterns, not clinical trials of the combined Wolverine Stack
Group I received vehicle (5% DMSO + olive oil), Group II received atorvastatin (ATO, 80 mg/kg), Group III received ATO (80 mg/kg) plus CoQ10 (10 mg/kg), and Group IV received ATO for 21 days followed by CoQ10 for 21 days